Medical AI Alliance
← Company Index
Biotech & Drug DiscoveryKOSDAQ 09570036 trials

Genexine, Inc.

Official website

KOSDAQ-listed biotech that launched the anemia drug EFESA (GX-E4) in Indonesia and co-develops the growth hormone candidate GX-H9 with China's TJ Bio.

As of 2026-10-10, Genexine, Inc. has 49 PubMed-indexed papers on record (counted by the MAA Company Index from its own matching of public databases).

Price

Change

Market cap

Business overview

Source: DART corporate disclosure

Founded in 1999 and listed on KOSDAQ in 2009, Genexine develops antibody-fusion protein therapeutics and gene therapy vaccines. Its anemia treatment for chronic kidney disease, EFESA (GX-E4, efepoetin alfa), completed Phase 3 trials across Indonesia, Korea, Malaysia, the Philippines, Thailand, Taiwan, and Australia, received its first marketing approval in Indonesia in October 2023, launched there in April 2024, and was submitted for approval in Korea in November 2024. Its immuno-oncology candidate GX-I7 and DNA vaccine GX-188E are being tested in combination with checkpoint inhibitors such as Keytruda and Opdivo, while its long-acting growth hormone candidate GX-H9 is in Phase 3 trials conducted through an open-innovation partnership with China's TJ Bio.

Products & technology

  • EFESA (GX-E4, efepoetin alfa)Anemia treatment for non-dialysis chronic kidney disease patients

Clinical trials

data.go.kr

36 MFDS clinical trial authorisations · 2012–2024 (Phase 1 14 · Phase 2 9 · Phase 1b 4 · Phase 1/2 4 · Phase 3 3)

  • Phase 1GX-E42024-05-28

    1 trial site

  • Phase 3GX-E42023-11-23

    5 trial sites

  • Phase 2GX-I72021-11-10

    3 trial sites

  • Phase 3GX-E42021-03-31

    9 trial sites

  • Phase 1GX-19/GX-19N2021-01-29

    2 trial sites

  • Phase 1/2aGX-19/GX-19N2020-12-11

    6 trial sites

  • Phase 1bGX-I72020-08-07

    1 trial site

  • Phase 1/2aGX-19/GX-19N2020-06-11

    2 trial sites

  • Phase 1GX-P12020-03-31

    2 trial sites

  • Phase 1GX-2002019-09-10

    2 trial sites

  • Phase 1/2GX-I72019-05-27

    1 trial site

  • Phase 1/2GX-I72018-11-30

    12 trial sites

Show 24 more
  • Phase 1bGX-I72018-09-20

    2 trial sites

  • Phase 1GX-2002018-06-22

    3 trial sites

  • Phase 3GX-E42018-03-13

    2 trial sites

  • Phase 1bGX-I72018-03-09

    5 trial sites

  • Phase 1bGX-I72017-12-27

    3 trial sites

  • Phase 1/2GX-188E2017-06-14

    9 trial sites

  • Phase 1/2GX-302017-05-22

    10 trial sites

  • Phase 1GX-022017-01-25

    1 trial site

  • Phase 1GX-I72016-11-30

    4 trial sites

  • Phase 1GX-I72016-06-01

    1 trial site

  • Phase 2GX-188E2016-03-17

    9 trial sites

  • Phase 2GX-H9 (hGH-hyFc)2016-02-22

    3 trial sites

  • Phase 2GX-G32016-02-16

    3 trial sites

  • Phase 1GX-0512015-07-06

    1 trial site

  • Phase 2GX-188E2015-01-08

    4 trial sites

  • Phase 1GX-E42014-10-21

    1 trial site

  • Phase 2GX-H9 (hGH-hyFc)2014-09-19

    8 trial sites

  • Phase 2GX-188E2014-03-11

    4 trial sites

  • Phase 1GX-0512014-02-21

    1 trial site

  • Phase 1GX-188E2014-01-08

    1 trial site

  • Phase 2GX-E42013-11-22

    15 trial sites

  • Phase 2HB-1102013-11-05

    1 trial site

  • Phase 1GX-G32013-06-26

    1 trial site

  • Phase 1GX-188E2012-05-30

    1 trial site

Global clinical trials

ClinicalTrials.gov · sponsor-matched
Show 26 more trials

R&D and key agreements

Source: DART corporate disclosure

GX-I7 · 말기고형암, 교모세포종, 삼중음성유방암, 미만성거대B세포림프종 등 · 임상1b~2상(다수 병용임상) · Improves tumor-associated lymphopenia and enhances antitumor T-cell immunity; combined with Keytruda, Avastin, Temodal, and Kymriah in various trials

GX-188E · HPV16/18 유래 자궁경부암·두경부암 · 임상1b~2상 · HPV DNA vaccine combined with GX-I7 and checkpoint inhibitors Keytruda/Opdivo

GX-H9 · 성인·소아 성장호르몬 결핍증 · 성인 임상2a상, 소아 임상3상(TJ Bio) · Long-acting growth hormone dosed weekly or biweekly; Phase 3 conducted with China's TJ Bio via open innovation

GX-G3 · 호중구감소증(항암제 투여 비골수성 종양) · 임상2상(ILKOGEN) · Improved efficacy and safety versus PEGylated G-CSF

GX-G6 · 제2형 당뇨병 · 임상3상(CSPC) · Long-acting GLP-1 receptor agonist

GX-P1 · 자가면역질환, 뇌염증질환 · 임상1~1b상 · Mechanism based on inducing T-cell immune tolerance

Key disclosures

KRX KIND via OpenDART

Publications

PubMed · affiliation-matched
Show 39 more publications

Patents

KIPRIS · applicant-matched
Show 207 more patents

AI reads

MAA server logs · IP-verified
92
Times AI engines pulled Genexine, Inc.'s records

Pulled records become part of each AI's index and keep feeding its answers. When an AI cites from that index, nothing reaches our server — so actual citations are uncounted here and exceed this number.

13
Fetched fresh mid-answer

Times an AI needed something not yet in its index and fetched this page fresh while answering. Citations served from the index leave no trace here.

79
Index crawls

Collected as raw material for future answers.

0
Direct AI-tool queries (MCP)

Queries from users who connected this index to their own AI.

18
live 3
Last 7 days
64
live 6
Last 30 days
92
live 13
All time
  • OpenAIChatGPT-Userlive13
  • OpenAIOAI-SearchBot68
  • PerplexityPerplexityBot5
  • GoogleGoogleOther3
  • AnthropicClaudeBot2
  • MicrosoftBingbot1

Measured since Aug 27, 2026 · 5 AI engines · last read Oct 9, 2026

User-agent strings can be forged, so we do not count them at face value. We count only requests matched against vendor-published IP ranges, or confirmed by forward-verified reverse DNS. MCP queries are actual calls to this index's tool endpoint.

Connect this index to your AI tool →

Connect this company index directly to your AI

Connect it to ChatGPT or Claude, and your AI queries the full record — profiles, financials, stock data, regulatory approvals, clinical trials, publications and patents — for Genexine, Inc. and every listed Korean medical, bio and AI company.

How to connect (MCP)
Not yet compiled: business overview · regulatory approvals. Send us materials and we will add them

Companies in the same categoryBiotech & Drug Discovery

AHNLAB,INC.100

KOSDAQ-listed integrated security company behind the V3 antivirus and AhnLab TrusGuard and XDR solutions.

Inventage Lab Inc.100

Drug delivery system company behind the long-acting injectable platform IVL-DrugFluidic and the LNP delivery platform IVL-GeneFluidic.

ORGANOIDSCIENCES LTD.100

Organoid-based biotech founded 2018, KOSDAQ-listed 2025, developing the ATORM-C regenerative therapeutic and ODISEI evaluation solution.

Eone Diagnomics Genome Center Co., Ltd.85

EDGC, a Korea-US joint venture of Eone Medical Foundation and Diagnomics, offers the NIPT service NICE and liquid biopsy OncoCatch.

SK Chemicals Co., Ltd.85

A diversified SK group company operating eco-friendly chemical materials alongside pharmaceutical products like Joins and vaccines through subsidiary SK Bioscience.

CG Invites Co., Ltd.85

Genomics and drug developer behind the osteoarthritis drug Acelex and the AI-driven healthcare platform Invites Loop.

Y-Biologics, Inc85

KOSDAQ-listed antibody biotech developing the next-generation immuno-oncology candidate Multi-AbKine on its fully human antibody library Ymax®-ABL.

GC Corp.85

A holding company overseeing 54 affiliates including its main biopharmaceutical subsidiary GC, with no direct product manufacturing of its own.

Prestige BioPharma Limited85

Founded in 2015 and listed on KOSPI in 2021, Prestige BioPharma develops antibody biosimilars and novel antibody drugs including Tuznue.

GENEMATRIX INC.85

KOSDAQ-listed biotech company developing molecular diagnostics with proprietary C-Tag technology and the NeoPlex product line.

SillaJen, Inc.85

SillaJen, Inc., founded in 2006 and listed on KOSDAQ in 2016, develops the oncolytic virus immunotherapy Pexa-Vec.

SK Bioscience Co.,Ltd84

A vaccine specialist developing in-house products such as SKYCellflu and SKYZoster while also serving as CDMO for AstraZeneca and Novavax.

Sources and updates

Counts on this page are not company-reported figures. MAA matched records from DART, the Korean MFDS, the US FDA, ClinicalTrials.gov, PubMed and KIPRIS to this company itself, by business registration number or registered name, never by name similarity. They may differ from figures the company publishes.

Company basics
Korea Exchange · DART
Business content
Compiled from disclosure filings
Approvals & clinical trials
Korean MFDS (data.go.kr) · US FDA openFDA — updated weekly
Key disclosures
KRX KIND via OpenDART exchange filings — updated daily
Global clinical trials
ClinicalTrials.gov (US NIH) — sponsor-matched, updated weekly
Financials
DART corporate disclosure filings — annual
Publications
PubMed (US National Library of Medicine) — affiliation-matched, updated daily
Patents
KIPRIS (Korea Institute of Patent Information) — applicant-matched, updated monthly
AI reads
Our server logs, IP-verified every 6 hours
AI visibility
Measured 2026-10-01

This page is compiled from public sources without the company's involvement. If anything is inaccurate or incomplete, please let us know. Materials provided by the company are labelled as such.

Request a correction or addition